media – Page 9 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

HEC Pharmaceuticals is listed on the Hong Kong Stock Exchange today

On August 7, Guangdong HEC Pharmaceutical Co., Ltd. (hereinafter referred to as ” HEC Pharma “) was listed on the Main Board of the Hong Kong Stock Exchange Limited (hereinafter referred to as “HKEX”). As the first H-share merger and privatization plus introduction case, HEC Pharma merged its Hong Kong-listed subsidiary Yichang HEC Pharmaceutical with the acquisition ofChangjiang Pharmaceutical Co., Ltd. has been fully listed. This is not only a milestone in the development history of this company that has been deeply engaged in innovation for 20 years, but also marks the beginning of the development of China’s innovative drugs.Asset SecuritiesThis is a breakthrough in the exploration of localization and internationalization. Industry insiders pointed out that this move not only breaks the time barrier of traditional capital operation methods, reduces the financial friction costs generated by corporate acquisitions, and realizes the connection between resource integration and capital upgrading, but also ...
- Source: drugdu
- 46
- August 7, 2025
Kelun Botai’s market value exceeds 100 billion

Today (August 5), Kelun Biotech’s market capitalization exceeded HK$100 billion for the first time, becoming a highly anticipated company in the innovative pharmaceutical sector. This is not only a milestone for the company itself, but also a significant milestone in the development of innovative pharmaceutical companies in China. The rise in Kelun Botai’s stock price can be described as an inspirational story of ups and downs. Since its listing on the Hong Kong Stock Exchange in July 2023, its share price and market capitalization have experienced a turbulent journey. Initially, despite the promise of a robust pipeline of innovative drugs, the company suffered a significant blow when two early-stage ADC programs in collaboration with Merck were terminated from clinical development, sending its share price into a brief downturn. However, the uncertainties surrounding innovative drug development haven’t hindered Kelun Biotech’s progress. In June 2024, the company, like a rising star, announced ...
- Source: drugdu
- 50
- August 7, 2025
【EXPERT Q&A】Why is it essential to implement the Unique Device Identification (UDI) system for medical devices?

Drugdu.com expert’s response: The Unique Device Identification (UDI) for medical devices serves as their “digital ID card,” and its application is a core tool for enhancing industry management efficiency and safeguarding public safety in medical device usage. The specific reasons are as follows: I. Full Lifecycle Traceability: Precise Problem Identification and Risk Reduction 1. Rapid Recall of Problematic Devices: UDI connects the entire chain of production, distribution, and usage through a unique code, enabling the localization of problematic batches or individual devices within hours. For instance, the U.S. Food and Drug Administration (FDA) completed a global recall of faulty heart stents in two days using UDI, a process that traditionally took weeks, significantly reducing patient risks. 2. Adverse Event Monitoring and Analysis: By linking UDI with patient data, the usage effectiveness of devices can be tracked, and correlations between adverse reactions and specific models or batches can be analyzed, providing data-driven support ...
- Source: drugdu
- 76
- August 6, 2025
Australian study finds lasting relief for back pain through cognitive functional therapy

Australian research has shown that a personalized program that helps people with chronic, disabling low back pain better understand their condition and take charge of its management produces large benefits that are sustained over three years. In the RESTORE trial, conducted at centres in Sydney and Perth, a seven-session program of cognitive functional therapy (CFT) delivered by specially trained physiotherapists significantly reduced people’s back pain and improved their function, compared with usual care. Data just published in medical journal The Lancet Rheumatology show these improvements were largely maintained over three years of follow-up. The persistent effect of CFT over time is a new and very important finding, says lead author Professor Mark Hancock, Professor of Physiotherapy at Macquarie University. “This the first large, high-quality study investigating the long-term impact of CFT, and shows that it’s effective and remains effective. In fact, our previous systematic review shows there are relatively few ...
- Source: drugdu
- 61
- August 6, 2025
New Drug May Fight a Deadly Bone Marrow Disorder

By Dennis Thompson HealthDay ReporterTUESDAY, Aug. 5, 2025 (HealthDay News) — A recently approved leukemia pill also might help some patients diagnosed with a deadly bone marrow disorder, a new pilot study says. About 3 in 5 patients with myelodysplastic syndrome (MDS) responded to treatment with olutasidenib (Rezlidhia), which the U.S. Food and Drug Administration (FDA) approved in 2022 for patients with acute myeloid leukemia, researchers reported recently in the journal Blood Advances. What’s more, about two-thirds of patients who previously required regular blood transfusions for the condition no longer needed them, results show. “We saw really quite remarkable outcomes in a very high-risk MDS population, not only in response rates, but also in blood count improvement, long duration of response and improved overall survival,” lead researcher Dr. Justin Watts, chief of the leukemia section at the University of Miami Sylvester Comprehensive Cancer Center, said in a news release. The ...
- Source: drugdu
- 55
- August 6, 2025
Sanofi withdraws lipid-lowering drug Praluent from Chinese market

On August 4, a reporter from the International Financial News learned from SanofiChina has learned that the company has stopped supplying its new lipid-lowering drug, Praluent (alirocumab injection), to the Chinese market. The main reasons for the suspension are global supply issues and the company’s cardiovascular market strategy and pipeline optimization. According to industry media reports, many hospitals have recently received official notifications from Sanofi . Praluent confirms his withdrawal According to the data, Praluent is a new lipid-lowering drug of the PCSK9 inhibitor class, which is mainly used for the prevention of cardiovascular events, primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia. The drug is one of the first PCSK9 monoclonal antibodies to be marketed in the world. It was approved in the United States in 2015 and was included in the China Innovative Drug List in 2019.It will be included in the priority review catalog, ...
- Source: drugdu
- 73
- August 5, 2025
Menopa’s subsidiary, Lurasidone Hydrochloride API, received approval

On August 4, Mino Pharma(603538) announced that its subsidiary Anhui Minova Pharmaceutical Chemical Co., Ltd.’s lurasidone hydrochloride API has passed the CDE technical review of the National Medical Products Administration and obtained the ” Chemical Raw Materials”The drug’s registration number is Y20230000666, and its indication is the treatment of schizophrenia. The R&D investment totaled 1.35 million yuan (unaudited). The approval of the lurasidone hydrochloride API confirms that the product meets the relevant national drug registration requirements and is eligible for sale in the domestic market. This will further enrich the company’s product line, expand its business scope, and enhance its advantages in the integrated production of APIs and preparations. According to the IMS database, global sales of preparations for this product are expected to reach approximately US$309 million in 2024, with API sales reaching 13,457.74 kilograms. In the first quarter of 2025, Minopharm achieved revenue of 276 million yuan and ...
- Source: drugdu
- 57
- August 5, 2025
These 4 new drugs have no American subjects, but are listed in the United States

As global drug research and development enters a period of clinical globalization and diversified approval pathways, how drug regulatory agencies evaluate and accept data from different sources is no longer just a matter of technical judgment, but also involves institutional mutual trust, geopolitics, and even the reshaping of the industrial landscape. According to the FDA’s “Drug Trials Snapshots 2024” report, the FDA approved four drugs in 2024 without any U.S. subjects involved. This rare move was widely interpreted as the FDA’s loosening of its stance on global data sources under certain conditions. Zero American Subjects: Analyzing Trend Changes from Individual Cases In 2024, the FDA approved 50 new drugs, four of which did not include any U.S. subjects at all. The four drugs are: EXBLIFEP (drug for complicated urinary tract infections), PIASKY (a rare disease treatment for paroxysmal nocturnal hemoglobinuria), TEVIMBRA (a PD-1 drug for esophageal cancer), and UNLOXCYT (for ...
- Source: drugdu
- 51
- August 5, 2025
Weight Loss Diet Not Needed With Exercise for Hip OA Pain

A very-low-calorie diet and weight loss combined with exercise does not appear to offer any greater reductions in hip osteoarthritis (OA) pain compared to exercise alone, even in people who are overweight or obese. Overweight and obesity are considered risk factors for hip OA, yet there are conflicting data on whether weight loss reduces the need for hip joint replacement, researchers wrote in their August 4, 2025, report published in Annals of Internal Medicine. In this study, researchers randomly assigned 101 people in Australia with a BMI above 27 to either 1) a dietitian-supported ketogenic very low-calorie diet plus a home-based exercise program supported by regular physiotherapy consultations or 2) the exercise program alone for 6 months. All the participants were aged 50 years or older, had experienced significant hip pain for at least 3 months, and had radiographic evidence of femoral or acetabular osteophytes and joint space narrowing. Despite ...
- Source: drugdu
- 56
- August 5, 2025
A Saliva-Based Test for Breast Cancer Might Be Near

By Ernie Mundell HealthDay ReporterMONDAY, Aug. 4, 2025 (HealthDay News) — In a small new study, a handheld saliva-sampling device successfully detected breast cancer 100% of the time, researchers said. The study only involved 29 saliva samples, and more research is needed. However, the results remain “very exciting because this device could improve access to breast cancer screening and significantly reduce health care costs,” said study co-author Dr. Coy Heldermon, a breast oncologist at University of Florida Health in Gainesville. “If all holds true, it would be a game-changer,” he said in a university news release. Access to screening remains a barrier to spotting breast cancers early, when they are most amenable to treatment. The American Cancer Society currently recommends that average-risk women get their first mammogram at age 40, and an MRI if they have specific risk factors, such as a family history of the disease. Of course, mammograms ...
- Source: drugdu
- 49
- August 5, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.